低分子肝素钙雾化吸入治疗慢性肺源性心脏病中的疗效分析

目的 :探讨低分子肝素钙雾化吸入对慢性肺源性心脏病中的治疗价值。方法 :10 6例患者随机分为治疗组与对照组 ,对照组给予常规治疗 ,治疗组在常规治疗的基础上应用低分子肝素钙雾化吸入 ,10 0IU/kg ,q .12h ,疗程 7d ,治疗前后监测肺平均动脉压、动脉血气分析、血凝及纤溶指标 ,治疗后评估疗效。结果 :临床疗效治疗组优于对照组 (P <0 .0 5 ) ,治疗组肺平均动脉压下降优于对照组 (P <0 .0 5 ) ,动脉血氧分压升高治疗组优于对照组 (P <0 .0 5 ) ,血凝及纤溶指标有变化但未引起出血现象 ,治疗组血浆凝血酶原时间、凝血酶时间在治疗前后比较有显著差异 (P <0 .0 5 ) ,治疗后治疗组与对照组比较血浆凝血酶原时间、凝血酶时间变化有显著差异 (P <0 .0 5 )。结论 :低分子肝素钙雾化吸入可改善慢性肺源性心脏病的肺动脉压 ,改善肺通气功能。

The Effects of Low Molecular Weight Heparin Calcium Aerosol Inhalation in Chronic Pulmonary Heart Patients

Objective: To investigate the effects of LMWHCa aerosol inhalation in chronic pulmonary heart patients. Methods: 106 patients were randomly divided into two groups: the therapy group and the control group. The control group was routine treated.The therapy group was treated by LMWHCa aerosol inhalation 100IU/kg q.12h than the control group. One course of treatment was 7 days.The other treatment of the therapy group was similar to the control group. The pulmonary average arterial pressure, the arterial blood-gas analysis, the blood coagulated and the fibrinolysis datas were determined. Results: The therapy group was better than the control group in the clinical efficiency ( P<0.05), in declining pulmonary average arterial pressure (P<0.05) and improving the oxygen pressure of blood ( P<0.05).The blood coagulated and the fibrinolysis datas had changed,but had no hemorrhage phenomenon ; the datas of the plasma prothrombin time and the thrombin time had changed after treatment in the therapy group (P<0.05), after treatment, there was difference between the therapy group and the control group in the datas of the plasma prothrombin time and the thrombin time (P<0.05). Conclusion:LMWHCa aerosol inhalation could improve clinical efficiency, decline pulmonary arterial pressure and improve ventilate function.